Prospective studies and next steps
As the demands for clinical use and economic benefits of diagnostics tests have increased significantly in recent years, so has the need for prospective studies. In order to validate the clinical utility of IMMray™ PanCan-d, Immunovia has embarked in large prospective studies.
Currently, the company is involved in three ongoing prospective pancreatic cancer studies focusing on the main risk groups:
- PanFAM-1 for Familiar/hereditary pancreatic cancer risk group
- PanDIA-1 for New onset diabetes type II – associated pancreatic cancer
- PanSYM-1 for risk groups with vague symptom profiles associated to pancreatic cancer
Once the studies are completed, the results will be the basis for applying for IMMray™ PanCan-d reimbursement and inclusion in national guidelines.